Seres Therapeutics (MCRB) Competitors $7.70 -0.54 (-6.55%) Closing price 04:00 PM EasternExtended Trading$7.72 +0.02 (+0.26%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. IMMP, RNAC, AURA, CGC, TSVT, ITOS, TERN, GLUE, LFCR, and ALLOShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Immutep (IMMP), Cartesian Therapeutics (RNAC), Aura Biosciences (AURA), Canopy Growth (CGC), 2seventy bio (TSVT), iTeos Therapeutics (ITOS), Terns Pharmaceuticals (TERN), Monte Rosa Therapeutics (GLUE), Lifecore Biomedical (LFCR), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Immutep Cartesian Therapeutics Aura Biosciences Canopy Growth 2seventy bio iTeos Therapeutics Terns Pharmaceuticals Monte Rosa Therapeutics Lifecore Biomedical Allogene Therapeutics Immutep (NASDAQ:IMMP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability. Do analysts rate IMMP or MCRB? Immutep presently has a consensus target price of $7.00, indicating a potential upside of 260.82%. Seres Therapeutics has a consensus target price of $73.67, indicating a potential upside of 856.71%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Immutep.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immutep 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Seres Therapeutics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Does the MarketBeat Community prefer IMMP or MCRB? Seres Therapeutics received 219 more outperform votes than Immutep when rated by MarketBeat users. However, 72.56% of users gave Immutep an outperform vote while only 70.99% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformImmutepOutperform Votes31272.56% Underperform Votes11827.44% Seres TherapeuticsOutperform Votes53170.99% Underperform Votes21729.01% Do insiders & institutionals believe in IMMP or MCRB? 2.3% of Immutep shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 3.1% of Immutep shares are held by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is IMMP or MCRB more profitable? Company Net Margins Return on Equity Return on Assets ImmutepN/A N/A N/A Seres Therapeutics N/A N/A -55.08% Which has more risk and volatility, IMMP or MCRB? Immutep has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.89, indicating that its share price is 189% more volatile than the S&P 500. Does the media favor IMMP or MCRB? In the previous week, Immutep had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Immutep and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.03 beat Immutep's score of 0.12 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immutep 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, IMMP or MCRB? Immutep has higher earnings, but lower revenue than Seres Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmutep$5.14M55.12-$28.01MN/AN/ASeres Therapeutics$126.33M0.53-$113.72M-$4.60-1.67 SummarySeres Therapeutics beats Immutep on 7 of the 13 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.24M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-33.488.9226.8419.71Price / Sales0.53250.95391.39116.98Price / CashN/A65.8538.2534.62Price / Book-22.006.466.794.50Net Income-$113.72M$143.98M$3.23B$248.18M7 Day Performance13.74%3.04%4.07%1.14%1 Month Performance2.91%7.44%12.52%15.20%1 Year Performance-57.70%-2.46%16.83%6.56% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.4752 of 5 stars$7.70-6.6%$73.67+856.7%-56.6%$67.24M$126.33M-33.48330Positive NewsIMMPImmutep1.5354 of 5 stars$1.87+1.1%$8.50+354.5%-35.2%$273.09M$5.14M0.002,021RNACCartesian Therapeutics1.5333 of 5 stars$10.44+5.5%$42.50+307.1%-60.4%$270.78M$38.91M-0.2064News CoverageAnalyst RevisionAURAAura Biosciences2.4576 of 5 stars$5.35+2.3%$22.75+325.2%-16.5%$268.70MN/A-3.0950Earnings ReportInsider TradeGap UpCGCCanopy Growth1.4028 of 5 stars$1.46+11.5%$2.00+37.0%-82.5%$268.44M$276.75M-0.383,150Trending NewsTSVT2seventy bio1.5274 of 5 stars$5.00+0.2%$4.25-15.0%N/A$266.15M$37.86M-2.69440News CoveragePositive NewsITOSiTeos Therapeutics2.978 of 5 stars$6.92+3.9%$25.50+268.5%-53.8%$264.86M$35M-2.2090Analyst RevisionHigh Trading VolumeTERNTerns Pharmaceuticals4.0965 of 5 stars$3.02-0.7%$18.38+508.4%-49.6%$263.76MN/A-2.5640News CoveragePositive NewsGap DownGLUEMonte Rosa Therapeutics2.1842 of 5 stars$4.27+4.4%$15.50+263.0%-16.0%$262.65M$75.62M-2.3390Positive NewsGap UpLFCRLifecore Biomedical1.2466 of 5 stars$6.98+0.1%$8.00+14.6%+11.7%$258.43M$130.31M-12.46690Analyst ForecastALLOAllogene Therapeutics3.4734 of 5 stars$1.17+0.9%$9.29+693.9%-55.2%$255.89M$22,000.00-0.75310Analyst Revision Related Companies and Tools Related Companies IMMP Competitors RNAC Competitors AURA Competitors CGC Competitors TSVT Competitors ITOS Competitors TERN Competitors GLUE Competitors LFCR Competitors ALLO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
